IGF1R and lung cancer: Although additional epidemiological and translational studies using longitudinal data from a large population are needed to ensure relationships between CCB medication and clinical outcomes, these findings suggest the biological plausibility of blocking Ca2+-mediated activation of the IGF-1R signalling cascade in lung cancer prevention.